Sophia Genetics reports Q1 EPS (27c), consensus (24c)

Reports Q1 revenue $21.69M, consensus $20.4M. “We started 2026 strong, delivering 22% year-over-year revenue growth and a record 108,000 genomic analyses on SOPHiA DDMTM,” said Jurgi Camblong, Chief Executive Officer and Co-Founder of SOPHiA GENETICS (SOPH). “Demand for our platform continues to grow, as U.S. hospitals and laboratories increasingly look to launch Ai-powered precision medicine capabilities, and customers across the globe continue to show strong interest in new applications such as Liquid Biopsy and Enhanced Exomes.”